{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:29:17Z","timestamp":1791116957633,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2002,9,1]],"date-time":"2002-09-01T00:00:00Z","timestamp":1030838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2002,9]]},"DOI":"10.1006\/biol.2002.0327","type":"journal-article","created":{"date-parts":[[2002,10,8]],"date-time":"2002-10-08T11:07:34Z","timestamp":1034075254000},"page":"187-196","source":"Crossref","is-referenced-by-count":47,"title":["Purity of Spiking Agent Affects Partitioning of Prions in Plasma Protein Purification"],"prefix":"10.1006","volume":"30","author":[{"given":"M.","family":"Vey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Weimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gr\u00f6ner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1006\/biol.2002.0327_RF1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3201\/eid0701.010102","article-title":"Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution and current concerns","volume":"7","author":"Brown","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"10.1006\/biol.2002.0327_RF2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/bmj.322.7290.841","article-title":"Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease","volume":"322","author":"Brown","year":"2001","journal-title":"BMJ"},{"key":"10.1006\/biol.2002.0327_RF3","series-title":"Biological Safety\u2014 Principles and Practices, Third Edition","first-page":"187","article-title":"Prion diseases Ch 12","author":"Baron","year":"2000"},{"key":"10.1006\/biol.2002.0327_RF4","unstructured":"European Agency for the Evaluation of Medicinal Products (EMEA), Report of EMEA Expert Workshop on Human TSEs and Plasma-Derived Medicinal Products, 15\u201316 May 2000"},{"key":"10.1006\/biol.2002.0327_RF5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0140-6736(01)05411-3","article-title":"Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues","volume":"358","author":"Bruce","year":"2001","journal-title":"Lancet"},{"key":"10.1006\/biol.2002.0327_RF6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(01)05403-4","article-title":"Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay","volume":"358","author":"Wadsworth","year":"2001","journal-title":"Lancet"},{"key":"10.1006\/biol.2002.0327_RF7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-3148.1999.009001003.x","article-title":"Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy","volume":"9","author":"Foster","year":"1999","journal-title":"Transfus Med"},{"key":"10.1006\/biol.2002.0327_RF8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0166-0934(99)00135-4","article-title":"Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein","volume":"84","author":"Lee","year":"2000","journal-title":"J Virol Methods"},{"key":"10.1006\/biol.2002.0327_RF9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1537-2995.2001.41040449.x","article-title":"A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins","volume":"41","author":"Lee","year":"2001","journal-title":"Transfusion"},{"key":"10.1006\/biol.2002.0327_RF10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1423-0410.2000.7820086.x","article-title":"Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products","volume":"78","author":"Foster","year":"2000","journal-title":"Vox Sang"},{"key":"10.1006\/biol.2002.0327_RF11","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1537-2995.1999.39111169.x","article-title":"Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans","volume":"39","author":"Brown","year":"1999","journal-title":"Transfusion"},{"key":"10.1006\/biol.2002.0327_RF12","doi-asserted-by":"crossref","first-page":"14945","DOI":"10.1073\/pnas.93.25.14945","article-title":"Subcellular colocalization of the cellular and scrapie prion protein in caveolae-like membranous domains","volume":"93","author":"Vey","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1006\/biol.2002.0327_RF13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/0003-9861(87)90380-8","article-title":"Isolation and structural studies of the intact scrapie agent protein","volume":"258","author":"Bolton","year":"1987","journal-title":"Arch Biochem Biophys"},{"key":"10.1006\/biol.2002.0327_RF14","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1128\/JVI.65.3.1340-1351.1991","article-title":"Scrapie rod formation requires both detergent extraction and limited proteolysis","volume":"65","author":"McKinley","year":"1991","journal-title":"J Virol"},{"key":"10.1006\/biol.2002.0327_RF15","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/2654","article-title":"Eight prin strains have PrPSc molecules with different conformations","volume":"4","author":"Safar","year":"1998","journal-title":"Nat Med"},{"key":"10.1006\/biol.2002.0327_RF16","series-title":"Statistical Method in Biological Assay. Third edition","author":"Finney","year":"1978"},{"key":"10.1006\/biol.2002.0327_RF17","doi-asserted-by":"crossref","first-page":"31479","DOI":"10.1074\/jbc.C100278200","article-title":"A protease resistant PrP isoform is present in urine of animals and humans affected with prion diseases","volume":"276","author":"Shaked","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1006\/biol.2002.0327_RF18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/ja01207a034","article-title":"Preparation and properties of serum and plasma proteins. IV. A system for the separation into fraction of the protein and lipoprotein components of biological tissues and fluids","volume":"68","author":"Cohn","year":"1946","journal-title":"J Am Chem Soc"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105602903271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105602903271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,7]],"date-time":"2020-03-07T10:25:17Z","timestamp":1583576717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1045105602903271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,9]]}},"alternative-id":["S1045105602903271"],"URL":"https:\/\/doi.org\/10.1006\/biol.2002.0327","relation":{},"ISSN":["1045-1056"],"issn-type":[{"value":"1045-1056","type":"print"}],"subject":[],"published":{"date-parts":[[2002,9]]}}}